Immunotherapy for pancreatic cancer using iPS cell-derived dendritic cell and autophagy-inducing oncolytic virus
| Project/Area Number |
25670560
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
General surgery
|
|---|
| Research Institution | Wakayama Medical University |
|---|
Principal Investigator |
Yamaue Hiroki 和歌山県立医科大学, 医学部, 教授 (20191190)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
Nakamori Mikihito 和歌山県立医科大学, 医学部, 准教授 (10322372)
Kawai Manabu 和歌山県立医科大学, 医学部, 講師 (40398459)
Ojima Toshiyasu 和歌山県立医科大学, 医学部, 講師 (60448785)
Hirono Seiko 和歌山県立医科大学, 医学部, 講師 (60468288)
谷 眞至 滋賀医科大学, 医学部, 教授 (60236677) [Withdrawn]
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | 膵癌 / 免疫療法 / 樹状細胞 / 癌治療用ウイルス / オートファジー / 遺伝子治療 / iPS細胞 / 癌 / iPS / 腫瘍溶解型ヘルペスウイルス / iPS由来樹状細胞 |
|---|
| Outline of Final Research Achievements |
We developed recombinant oncolytic herpes simplex viruses that possess certain antitumor functions and are useful for gastric cancer therapy. A third-generation oncolytic herpes simplex virus type 1(T-01) was used as the backbone to insert foreign sequences. Oncolytic herpes simplex viruses expressing suppressor of cytokine signaling 3 (T-SOCS-3) were constructed, evaluated, and proved to be therapeutic potential. T-SOCS-3 may be a new agent against pancreatic cancer in the near future, and a progress has been made in the basic development of next generation onoclytic virotherapy.In addition, we confirmed that iPS cell derived dendritic cell was able to enhance antitumor immunity at the oncolyitic condition of tumor microenvironment.
|
Report
(4 results)
Research Products
(42 results)
-
-
-
-
[Journal Article] Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study.2015
Author(s)
Yamaue H, Tsunoda T, Tani M, Miyazawa M, Yamao K, Mizuno N, Okusaka T, Ueno H,Boku N, Fukutomi A, Ishii H, Ohkawa S, Furukawa M, Maguchi H, Ikeda M, Togashi Y,Nishio K, Ohashi Y.
-
Journal Title
Cancer Sci
Volume: 106
Pages: 883-890
DOI
Related Report
Peer Reviewed / Open Access / Acknowledgement Compliant
-
-
[Journal Article] A:Validation of a Nomogram for Predicting the Probability of Carcinoma in Patients With Intraductal Papillary Mucinous Neoplasm in 180 Pancreatic Resection Patients at 3 High-Volume Centers.2015
Author(s)
Shimizu Y, Yamaue H, Maguchi H, Yamao K, Hirono S, Osanai M, Hijioka S, Kanemitsu Y, Sano T, Senda Y, Bhatia V, Yanagisawa A
-
Journal Title
Pancreas
Volume: 44
Pages: 459-64
Related Report
Peer Reviewed
-
-
-
[Journal Article] Identification of Risk Factors for Pancreatic Exocrine Insufficiency After Pancreaticoduodenectomy Using a 13C-Labeled Mixed Triglyceride Breath Test.2015
Author(s)
Hirono S, Murakami Y, Tani M, Kawai M, Okada K, Uemura K, Sudo T, Hashimoto Y, Nakagawa N, Kondo N, Yamaue H
-
Journal Title
World J Surg
Volume: 39
Pages: 516-25
Related Report
Peer Reviewed
-
-
-
-
-
[Journal Article] Phase II clinical study of alternate-day oral therapy with S-1 as first-line chemotherapy for locally advanced and metastatic pancreatic cancer.2014
Author(s)
Yamaue H, Satoi S, Kanbe T, Miyazawa M, Tani M, Kawai M, Hirono S, Okada K, Yanagimoto H, Kwon AH, Mukouyama T, Tsunoda H, Chijiiwa K, Ohuchida J, Kato J, Ueda K, Yamaguchi T, Egawa S, Hayashi K, Shirasaka T
-
Journal Title
Cancer Chemother Pharmacol
Volume: 73
Pages: 97-102
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
